Results 21 to 30 of about 186,761 (273)

Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues

eLife, 2021
Although Pembrolizumab-based immunotherapy has significantly improved lung cancer patient survival, many patients show variable efficacy and resistance development.
Teresa WM Fan, Richard M Higashi, Huan Song, Saeed Daneshmandi, Angela L Mahan, Matthew S Purdom, Therese J Bocklage, Thomas A Pittman, Daheng He, Chi Wang, Andrew N Lane   +10 more
doaj   +1 more source

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

Liver Cancer, 2021
Introduction: KEYNOTE-240 investigated the efficacy and safety of pembrolizumab plus best supportive care (BSC) in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC).
Masatoshi Kudo, Ho Yeong Lim, Ann-Lii Cheng, Yee Chao, Thomas Yau, Sadahisa Ogasawara, Masayuki Kurosaki, Naoki Morimoto, Kazuyoshi Ohkawa, Tatsuya Yamashita, Kyung-Hun Lee, Erluo Chen, Abby B. Siegel, Baek-Yeol Ryoo   +13 more
doaj   +1 more source

Two‐year efficacy of SNK01 plus pembrolizumab for non‐small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial

Thoracic Cancer, 2022
Background A previous trial showed that autologous ex‐vivo expanded NK cell (SNK01) treatment combined with pembrolizumab showed better efficacy than pembrolizumab monotherapy in advanced non‐small cell lung cancer (NSCLC). This study was a 2‐year follow‐
Hyung Jun Park, Yong Man Kim, Jae Seob Jung, Wonjun Ji, Jae Cheol Lee, Chang‐Min Choi   +5 more
doaj   +1 more source

Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study

Cancer Medicine, 2023
Pembrolizumab, an anti‐programmed death 1 monoclonal antibody, has revolutionized the treatment of metastatic urothelial carcinoma. However, the optimal treatment duration for treatment responders has not been established.
Katsuhiro Ito, Yuki Kita, Akira Yokomizo, Jun Miki, Yuko Yoshio, Hiroaki Matsumoto, Takehiko Segawa, Takashi Karashima, Naotaka Nishiyama, Kazuto Imai, Shigetaka Suekane, Seiji Nagasawa, Shin Higashi, Hiroyuki Nishiyama, Hiroshi Kitamura, Takashi Kobayashi   +15 more
doaj   +1 more source

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy

Journal for ImmunoTherapy of Cancer, 2019
Pembrolizumab monotherapy has become the preferred treatment for patients with advanced non-small cell lung carcinoma (NSCLC) and a programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) of at least 50%.
Zuan Lin
doaj   +1 more source

Predictive biomarkers for checkpoint inhibitor-based immunotherapy: The Galectin-3 signature in NSCLCs [PDF]

, 2019
Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However, reliable predictive markers of tumor responsiveness are still lacking.
Bartolazzi A., Capalbo C., Filetti M., Marchetti P., Scafetta G.   +4 more
core   +1 more source

Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. [PDF]

, 2018
Metastatic non-small cell lung cancer (NSCLC) is a highly fatal and immunogenic malignancy. Although the immune system is known to recognize these tumor cells, one mechanism by which NSCLC can evade the immune system is via overexpression of programmed ...
Che, James, Dhar, Manjima, Di Carlo, Dino, Elashoff, David, Garon, Edward B, Goldman, Jonathan W, Grogan, Tristan, Kulkarni, Rajan P, Matsumoto, Melissa, Sollier Christen, Elodie, Wong, Jessica   +10 more
core   +3 more sources

A Case of Stevens-Johnson Syndrome/toxic epidermal necrolysis in a patient receiving chemo-immunotherapy with pemetrexed and pembrolizumab

Current Problems in Cancer: Case Reports, 2021
Chemo-immunotherapy consisting of pemetrexed and pembrolizumab is first line therapy for individuals with non-squamous non-small cell lung cancer without ALK or EGFR mutations.
Michael H. Storandt, Rishi Seth
doaj   +1 more source

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. [PDF]

, 2016
Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck ...
Berger, Raanan, Burtness, Barbara, Cheng, Jonathan D, Chow, Laura QM, Chung, Hyun Cheol, Dolled-Filhart, Marisa, Eder, Joseph Paul, Geva, Ravit, Gupta, Shilpa, Haddad, Robert, Kang, Hyunseok, Keam, Bhumsuk, Lee, Se-Hoon, Lin, Chia-Chi, Mahipal, Amit, Mehra, Ranee, Meister, Amy, Muro, Kei, Pathiraja, Kumudu, Seiwert, Tanguy Y, Tahara, Makoto, Weiss, Jared   +21 more
core   +2 more sources

Pembrolizumab induced-C3 glomerulonephritis and RBC cast nephropathy: a case report

BMC Nephrology, 2023
Background Immune checkpoint inhibitors (ICIs) are increasingly being used in the treatment of several cancers. Pembrolizumab is an anti-programmed cell death-1 (anti-PD-1) monoclonal antibody that is approved for the treatment of metastatic non-small ...
Zhi Yang, Huan Xu, Shenju Gou, Hongyan Wu, Zhangxue Hu   +4 more
doaj   +1 more source